Business
OKYO Expands Scientific Advisory Board with the Appointment of International Expert Marta Sacchetti, MD, PhD
Dr. Sacchetti brings international expertise in clinical and translational research on ocular inflammatory and degenerative diseaseOKYO’s introduction to the
About this update from Okyo Pharma Limited
[{"type":"text","content":"Dr. Sacchetti brings international expertise in clinical and translational research on ocular inflammatory and degenerative diseaseOKYO’s introduction to the broader ophthalmology community at ASCRS drove strong engagement at Eyecelerator and ARVO LONDON and NEW YORK, May 19, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain (NCP) and for inflammatory eye diseases, today announced the expansion of their Scientific Advisory Board (SAB) with the appointment of Marta Sacchetti, MD, PhD. This appointment further enhances the Company’s global scientific network with premier European specialists. “Our world class Scientific Advisory Board is further strengthened by the addition of Marta Sacchetti, MD, PhD,” said Flavio Mantelli, MD, PhD, Chief Medical Officer of OKYO Pharma. “Her expertise in neuro-inflammatory corneal diseases brings critical insight into addressing the underlying nerve dysfunction driving neuropathic corneal pain (NCP) and will help shape our global clinical development strategy and execution.” Marta Sacchetti, MD, PhD is Associate Professor of Ophthalmology at Link University in Rome, Italy and brings extensive clinical, research, and industry experience in cornea and ocular surface diseases. Dr. Sacchetti’s previous experience as Global Head of Clinical Development, Ophthalmology & Neurotrophins at Dompé Farmaceutici will further strengthen the MAB’s global expertise in targeted nerve regeneration, modulating pain signaling, and advanced diagnostic insight. Her research focuses on degenerative, allergic, and neuroimmune diseases of the cornea and ocular surface. She authored numerous publications in international peer reviewed journals, abstracts for national and international conferences, and ophthalmology book chapters. Urcosimod is the first investigational therapy to receive an IND specifically for the treatment of neuropathic corneal pain and has been granted Fast Track designation by the U.S. Food and Drug Administration (FDA). About Neuropathic Corneal Pain (NCP) Neuropathic corneal pain (NCP) is a chronic, often debilitating condition characterized by severe pain and sensitivity of the eyes, and in some cases the face or head. It is thought to result from damage or dysfun...